News
The authors present an important set of data implicating ETFDH as an epigenetically suppressed gene in cancer with tumor suppressive functions. The evidence is solid, with the authors demonstrating ...
Clene (NASDAQ: CLNN) announced first quarter 2025 financial results and progress on its CNM-Au8 program for ALS and MS. The company is preparing for ...
Nine researchers from Utrecht have received funding in the 25th round of the NWO Open Competition ENW-XS. The grants (of up to 50,000 euros) are intended to enable small-scale, innovative and risky ...
Clene (NASDAQ: CLNN) announced it will participate in the D. Boral Capital Inaugural Global Conference on May 14, 2025, at The Plaza Hotel in New Yo ...
Clene Inc. (NASDAQ: CLNN), today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May 14, 2025, at The Plaza Hotel in New York City.Rob Etherington, ...
NAD+ therapy is on the rise among men seeking more than just a quick fix. From mental clarity and energy to longevity and ...
Innovative weight-loss drugs burst onto the scene about 10 years ago, promising a healthier, slimmer world. The downside, ...
In the ever-evolving world of biohacking, two trends have emerged as frontrunners in the quest for optimal performance: NAD boosters and smart supplements, also known as nootropics. As modern ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results